XNASRPID
Market cap44mUSD
Jan 07, Last price
1.04USD
1D
0.97%
1Q
16.85%
IPO
-95.68%
Name
Rapid Micro Biosystems Inc
Chart & Performance
P/E
—
P/S
1.99
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
23m
+31.44%
Net income
-52m
L-13.71%
CFO
-45m
L-23.00%
Earnings
May 23, 2025
Profile
Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in North America, Europe, and Asia. The company offers Growth Direct platform, which includes Growth Direct system, proprietary consumables, lab information management system connection software, and comprehensive customer support and validation services. Its platform automates and modernizes the manual microbial quality control (MQC) testing workflows for therapeutic modalities, such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company also provides installation and verification, technical training, and support services. Its solutions are used in environmental monitoring, water testing, bioburden, and sterility release testing applications. The company was formerly known as Genomic Profiling Systems, Inc. and changed its name to Rapid Micro Biosystems, Inc. in January 2007. Rapid Micro Biosystems, Inc. was incorporated in 2006 and is headquartered in Lowell, Massachusetts.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | 22,519 31.44% | 17,133 -26.25% | |||
Cost of revenue | 79,082 | 80,352 | |||
Unusual Expense (Income) | |||||
NOPBT | (56,563) | (63,219) | |||
NOPBT Margin | |||||
Operating Taxes | 31 | (576) | |||
Tax Rate | |||||
NOPAT | (56,594) | (62,643) | |||
Net income | (52,467) -13.71% | (60,806) -17.30% | |||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 366 | 886 | |||
BB yield | -1.15% | -1.85% | |||
| Debt | |||||
Debt current | 2,264 | 766 | |||
Long-term debt | 19,774 | 15,170 | |||
Deferred revenue | |||||
Other long-term liabilities | (5,951) | 229 | |||
Net debt | (72,926) | (122,502) | |||
| Cash flow | |||||
Cash from operating activities | (45,081) | (58,547) | |||
CAPEX | (1,845) | (6,740) | |||
Cash from investing activities | 42,153 | (93,469) | |||
Cash from financing activities | 149 | 693 | |||
FCF | (57,700) | (64,157) | |||
| Balance | |||||
Cash | 92,053 | 108,648 | |||
Long term investments | 2,911 | 29,790 | |||
Excess cash | 93,838 | 137,581 | |||
Stockholders' equity | (428,062) | (376,606) | |||
Invested Capital | 554,792 | 548,643 | |||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 43,024 | 42,454 | |||
Price | 0.74 -34.51% | 1.13 -89.38% | |||
Market cap | 31,838 -33.63% | 47,973 -89.13% | |||
EV | (41,088) | (74,529) | |||
EBITDA | (53,458) | (60,382) | |||
EV/EBITDA | 0.77 | 1.23 | |||
Interest | 1,778 | ||||
Interest/NOPBT | |||||